Luciano Martelotto: CD200R1, IL-17A, and the Future of Cancer Thrombosis Prevention
Luciano Martelotto, Director of Global Market Development for Single Cell at Waters Biosciences at Waters Corporation, shared a post on LinkedIn about a recent article by Dimitra Karagkouni et al., published in Science Translational Medicine, adding:
“An amazing paper from my dear friends Ioannis Vlachos, Dimitra Karagkouni and collabs…which also received the cover highlight!
For cancer patients, a blood clot can be just as dangerous as the tumor itself.
Venous thromboembolism (VTE) remains one of the leading causes of mortality in oncology, yet predicting who will clot and who will not has been an uphill clinical battle.
The current standard, the Khorana Score, often struggles in the clinic – failing to flag some patients at high risk while over-identifying others.
A brilliant new study by Karagkouni et al. in Science Translational Medicine is a masterclass in how translational medicine should work.
The research beautifully connects high-throughput proteomics, machine learning, and mechanistic immunology into a single, cohesive story with an immediate therapeutic angle.
The team analyzed over 1,100 plasma proteins from patients newly diagnosed with lung or gastric cancer.
Using a machine learning approach, they whittled this data down to an 11-protein panel. Combined with 5 clinical parameters (e.g., age, hemoglobin levels, etc), this model drastically outperformed standard prediction methods.
The paper moves beyond mere prediction into deep mechanistic biology. The team investigated CD200R1 (CD200 receptor 1), an immune checkpoint receptor that typically keeps inflammatory responses in check.
They noticed that a drop in plasma CD200R1 correlated heavily with elevated D-dimer levels and heightened thrombosis risk.
To prove causality, they turned to a knockout mouse model:
- Deleting CD200R1 led to an upsurge in the inflammatory cytokine IL-17A, causing localized endothelial inflammation and a distinct prothrombotic state.
- When the researchers administered an anti-IL-17A antibody, it neutralized the inflammation and successfully normalized thrombin-antithrombin complexes in vivo.
The most exciting implication here is the immediate potential for drug repurposing.
Anti-IL-17A biologics (like secukinumab) are already FDA-approved and widely used for inflammatory conditions like psoriasis.
This opens a tangible, testable hypothesis: could we use these existing drugs to actively mitigate clotting risks in cancer patients displaying a dysregulated CD200R1 pathway?
Of course, important translational hurdles remain.
We must validate these findings prospectively across broader cancer cohorts, and we need to carefully weigh how dampening IL-17A impacts the broader, incredibly complex tumor microenvironment.
Nevertheless, by elegantly bridging the gap between proteomics, immunothrombosis, and vascular biology, this study provides a blueprint for the future of personalized oncology care.
It is a must-read for anyone working at the intersection of cancer, immunology, and hemostasis.”
Title: Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17–driven endothelial activation
Authors: Dimitra Karagkouni, Marisa A Brake, Rushad Patell, Anna Falanga, Marina Marchetti, Laura Russo, Simon Mantha, Donna Neuberg, Thita Chiasakul, Marc Carrier, Philip S Wells, Robert E Gerszten, Robert Flaumenhaft, Daniel Hui, Ioannis S Vlachos, Sol Schulman, Jeffrey I Zwicker
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery